Turn £10k Into £18.5k With GlaxoSmithKline plc

Even during a troubled decade, GlaxoSmithKline plc (LON: GSK) shares have performed reasonably.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskI took a look recently at AstraZeneca, and was impressed to see an overall trebling in value over the past 10 years if all dividends were reinvested.

The FTSE 100‘s other big pharmaceuticals company, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) hasn’t been doing quite so well — for one thing, it hasn’t had its shares boosted by takeover fever.

A 20% gain?

If you’d invested £10,000 in GlaxoSmithKline shares 10 years ago, you’d have been paying around 1,191p apiece — and at that price you could have bagged 839 shares (ignoring dealing costs).

Now, the share price has only gained 21.5% over the period, and your ten grand would have grown to £12,149. While that might have matched cash in a savings account, we really expect better from investing in shares.

But that doesn’t include dividends, so what would those have added?

Rising dividends

GlaxoSmithKline has actually been paying pretty decent dividends, starting the period offering yields of around 3.5%. But that started ramping up in 2007 as the share price fell a little, reaching 5% by 2009 — and yields have remained close to that level since. 

One thing that does mean is that dividends alone would have easily been enough to beat cash sitting in the bank, without any share price gain!

Earnings per share (EPS) can be a little volatile, but even when EPS didn’t cover the dividend in 2010, Glaxo maintained the cash payment from its own resources — and EPS was back up to normal the next year.

Another five grand!

In total, GlaxoSmithKline would have paid you an extra £4,971 in dividends, taking your total to £17,120 — and a 71% rise is starting to look reasonable.

But what if, instead of taking and spending your cash handout each year, you had reinvested it in more Glaxo shares?

Before we look at that, let me mention a thing called pound cost averaging — it’s a fancy term that just means you’ll get more shares for the same money over a period when the price dips and recovers than if it had remained flat.

For Glaxo, what that means is that you’d have added just 24 new shares at the end of 2004 when the price was around 1,440p, but by 2007 when it had dropped to 1,210p you’d have scooped up 40 of them.

A decent result

Anyway, with dividends reinvested, you’d be ending the decade with £18,594 — and an 85.5% gain is really nothing to be sniffed at, especially for a share that has actually lagged the FTSE a little over the period (but with better than average dividend yields).

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Turning a £20k ISA into an annual second income of £30k? It’s possible!

This Fool UK writer is exploring how to harness the power of dividend shares and compound returns to build a…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

Can I turn £10k into a £1k passive income stream with UK shares?

Everyone talks about the magical 10% mark when it comes to passive income investing, but how realistic is it to…

Read more »

Investing Articles

3 market-beating international investment funds for a Stocks and Shares ISA

It always pays to look for new ways to add extra diversity to a Stocks and Shares ISA. I think…

Read more »

Grey cat peeking out from inside a cardboard box in a house
Investing Articles

Just released: April’s latest small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

The Anglo American share price soars to £25, but I’m not selling!

On Thursday, the Anglo American share price soared after mega-miner BHP Group made an unsolicited bid for it. But I…

Read more »

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »